NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global ...

NNVC NanoViricides, Inc. (NYSE:NNVC) is a clinical-stage biopharmaceutical company developing a new class of broad-spectrum ...

NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage pioneer in host-mimetic nanomedicine, affirmed its preparedness to address the continued ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

NanoViricides, Inc., a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update on its clinical program activities. Anil Diwan, the Company's President, and ...

NanoViricides is preparing to file an IND and transition into a clinical-stage biotech. Once NV-HHV-101 is in the clinic, the company expects to advance their HSV-1 “cold sores” and of HSV-2 ...

Late last year, NanoViricides was in the process of filing an Investigational New Drug application with the U.S. Food and Drug Administration for NV-HHV-101, its lead drug candidate for the ...

NanoViricides is rapidly moving towards Phase II Safety, Tolerability and Efficacy Evaluation of its Lead Drug candidate, NV-387, for the Treatment of MPOX disease. The Company has announced that ...

SHELTON, CT / ACCESS Newswire / March 11, 2025 / NanoViricides, Inc. (the "Company")(NYSE American:NNVC), a clinical-stage global leader developing revolutionary broad-spectrum antiviral drugs ...

SHELTON, CT / ACCESSWIRE / October 11, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel ...

NanoViricides, Inc. a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, has filed its quarterly report for its second quarter of ...

SHELTON, CT / ACCESSWIRE / May 26, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel ...